The Efficient Component Pricing Rule: Friend or Foe?

Kant: Friend or Foe of the Believer? Plantinga and Other American Christian Responses to Kant's Epistemology

Apocrine Metaplasia in Intraductal Papilloma with Foci of DCIS: A Friend or Foe?

Malignant papillary neoplasms of the breast comprise a number of microscopically distinct lesions, where apocrine metaplasia is commonly found in papillomas compared to other papillary lesions including papillary carcinomas. However, association of apocrine metaplasia in papilloma with Ductal Carcinoma in Situ (DCIS) is not very well defined. The lesions with apocrine metaplasia are not only di...

Friend-or-Foe Q-learning in General-Sum Games

This paper describes an approach to reinforcement learning in multiagent general-sum games in which a learner is told to treat each other agent as either a \friend" or \foe". This Q-learning-style algorithm provides strong convergence guarantees compared to an existing Nash-equilibrium-based learning rule.

Friend or Foe: Risk Factors and Behavioral Bias

Profitability and investment are becoming the new focus of empirical asset pricing. This paper examines the extent to which their return predictability is attributable to behavioral bias, specifically, investors’ tendency to anchor on 52-week high. Based on a return decomposition methodology developed by George, Hwang, and Li (2014), two profitability measures (operating profitability, return o...

NOACs; Friend or Foe?

New oral anticoagulants (NOAC’s) are becoming more popular as antithrombotic agents for the prevention of venous thromboembolism in atrial fibrillation and as prophylaxis in hip and knee surgery. With simple administration, rapid onset, few drug interactions and the absence of coagulation monitoring, NOAC’s appear as a friend in the prevention of thromboembolic events. Undoubtedly patients woul...